52results about "Calcitonins" patented technology

The present disclosure relates to a polypeptide construct for targeted delivery of a payload, comprising a natriuretic peptide receptor (NPR-C) ligand. Also provided is a conjugate comprising; a polypeptide construct for targeted delivery of a payload to NPR-C expressing cells. Further provided are compositions comprising the construct or the conjugate, and kits comprising the construct and a crosslinker, and methods and uses of the same.

The present invention relates to the field of pharmaceutical synthesis and provides a long-acting calcitonin analog and the use of the long-acting calcitonin analog in the manufacture of pharmaceuticals for treating diseases. The pharmaceutical composition is used for the prevention and treatment of osteoporosis, osteoosteitis, complex regional pain syndrome, and malignant osteolysis.

The invention relates to an application of a fatty acid-containing side chain in the aspects of improving the activity, activity selectivity and oral availability of a polypeptide derivative, a method for realizing the application and the polypeptide derivative modified by the side chain.

Provided herein are the use of fatty acid-containing side chains in improving the activity, activity selectivity, and oral availability of polypeptide derivatives, methods for achieving such use, and polypeptide derivatives modified by such side chains.

The present application provides a polypeptide and a polypeptide derivative or a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the polypeptide described herein or a derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The use of the above polypeptide, polypeptide derivative or a pharmaceutically acceptable salt thereof, or composition in the field of disease prevention / treatment is also provided.

The present disclosure provides a calcitonin analogue and a derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the analogue or the derivative or a pharmaceutically acceptable salt thereof and further comprising a pharmaceutically acceptable excipient, and use of the analogue, the derivative or a pharmaceutically acceptable salt thereof or the composition in the field of disease prevention / treatment.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

Peptides that exhibit amylin and calcitonin receptor agonist activity (DACRAs) are provided as well as prodrug derivatives thereof. Analogs having enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising such peptide analogs and therapeutic methods of using such peptide analogs are also provided.

A compound or derivative of a compound comprising a peptide chain that is an analog of amylin, a terminal -NH2 group attached to the C-terminus of the peptide chain, and an alkylene or alkenylene chain attached to the other end of the peptide chain; or a salt or solvate of the compound or derivative. The compounds, derivatives, and salts and related compositions are suitable for preventing or treating diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention relates generally to novel multi-agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, such as those that can be alleviated by weight loss, plasma glucose and lipid levels, insulin levels, and / or insulin secretion, control of positive inotropy, reduction of catabolism, slowing of gastric emptying, and prevention of neurodegeneration, including, but not limited to, food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels, and / or insulin secretion, control of positive inotropy, reduction of catabolism, slowing of gastric emptying, obesity, diabetes and diabetes-related conditions, liver fat-related inflammation and damage.

The present invention relates to a subtilisin BPN' variant or homologue thereof comprising new mutations compared to subtilisin BPN' as shown in SEQ ID NO: 2 or a homologous sequence thereof. Such mutations can occur at amino acid positions selected from the group consisting of L96, D99, A223 and S224. The present invention also relates to a method for the enzymatic synthesis of a peptide by coupling of peptide fragments, wherein said coupling is catalysed by said subtilisin BPN' variant or homologue thereof.

To provide a more effective medicament which is potent in vitro and potent against weight loss, which at the same time does not result in proportionally increased levels of side effects, which has improved pharmacokinetic properties, which has improved chemical stability, which is suitable for once weekly administration in humans, and / or which is suitable for oral administration.SOLUTION: The present invention relates to a GLP-1- / GIP- / amylin-receptor tri-agonist. This GLP-1- / GIP- / amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.SELECTED DRAWING: None

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention provides methods for inducing satiety and treating metabolic disorders, diabetes, obesity, and obesity-related conditions, comprising administration of metabolic hormones via nasal, topical gastrointestinal, or intrarectal routes.

The present application provides a polypeptide, and a derivative of the polypeptide or a pharmaceutically acceptable salt thereof. The present application further provides a pharmaceutical composition containing the polypeptide or the derivative or the pharmaceutically acceptable salt thereof of the present application, and a pharmaceutically acceptable adjuvant, and a use of the polypeptide, the derivative of the polypeptide or the pharmaceutically acceptable salt thereof, and the composition in the field of disease prevention / treatment.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention relates to the field of pharmaceutical synthesis, and provides a long-acting calcitonin analog and a use of the long-acting calcitonin analog for preparing a pharmaceutical composition for treating diseases. The pharmaceutical composition is used for prevention and treatment of osteoporosis, osteitis deformans, algoneurodystrophy, and malignant osteolysis.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention provides a fusion polypeptide, a kit and a detection method for procalcitonin detection. The provided SCFV antibodies fused to the large subunit and the small subunit of luciferase respectively can provide the best detection effect. When the fusion polypeptide is used for detecting the procalcitonin or the analogue thereof, excellent clinical comparison correlation is achieved, the detection time is shorter, the detection speed is higher, and a matched instrument is simple in structure.

A multi-arm, degradable polyethylene glycol derivative with a high molecular weight that does not cause vacuolation of cells is provided. A degradable polyethylene glycol derivative represented by the following formula (1):wherein n1 and n2 are each independently 45-950, W1 and W2 are each independently an oligopeptide of 2-47 residues, a1 and a2 are each independently 1-8, Q is a hydrocarbon chain having 2-12 carbon atoms and optionally containing an oxygen atom and / or a nitrogen atom, X1 and X2 are each independently a functional group capable of reacting with a bio-related substance, and L1, L2, L3, L4, L5 and L6 are each independently a divalent spacer.

A stable aqueous gel or semi-solid gel pharmaceutical composition comprising a water-soluble peptide having gel-forming ability, optionally in combination with appropriate excipients and therapeutic agents. Upon administration to an individual, the pharmaceutical composition forms a gel reservoir in which the gel nanostructure releases the peptide or encapsulated therapeutic drug for a longer period of time. The gel-forming compound can be formulated as an aqueous formulation, a suspension or a solid formulation, wherein the gel-forming polypeptide contained accounts for 0.01% to 99% of the total weight of the formulation. These formulations are useful for drug delivery and implantable drug depots, for long term delivery of therapeutic drugs, antigens or cells. Also provided are methods of preparing gel-forming compounds by gel formation enhancing motif modification compounds.

The invention relates to a calcitonin analogue and a derivative or pharmaceutically acceptable salt thereof. The invention relates to a pharmaceutical composition, which contains analogues or derivatives or pharmaceutically acceptable salts thereof, and further comprises pharmaceutically acceptable auxiliary materials. The analogues or derivatives or pharmaceutically acceptable salts and compositions of the analogues or derivatives are applied to the field of disease prevention / treatment.

Provided is a polypeptide or a derivative thereof or a pharmaceutically acceptable salt thereof, which has a structure as shown in formula (I) (U-X1SHX4SX6X7X8X9X10X11X12X13X14X15X16X17X18X19X20DX22PX24TDVGAGSX32-NH2) and a modification group. The structure as shown in formula (I) contains two amino acids Z1 or two amino acids Z2, wherein the positions of the two amino acids Z1 or the two amino acids Z2 are Xi and Xi+7, respectively, and i is any integer between 6 to 13. The modification group is linked to the two amino acids Z1 or the two amino acids Z2 via covalent bonds. The polypeptide or the derivative thereof has certain activation activity on both an amylin receptor and a calcitonin receptor, and has a longer in vivo half-life by means of modification with a side chain modification group, so as to support low-dose and low-frequency administration. The polypeptide or the derivative thereof can be used for preventing or treating metabolic-related diseases.

Provided in the present application is a polypeptide and a derivative of the polypeptide or a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the polypeptide or the derivative or a pharmaceutically acceptable salt thereof described in the present application, and a pharmaceutically acceptable excipient. Use of the polypeptide, the derivative of the polypeptide or a pharmaceutically acceptable salt thereof, or the composition as described above in the field of disease prevention / treatment is also provided.

Embodiments herein relate generally to peptides with agonistic or antagonistic activity to one or more human receptors selected from glucagon receptor, amylin receptor, calcitonin receptor, gastic inhibitory peptide (GIP) receptor and GLP-1 receptor. In some embodiments, the peptides disclosed herein are polyagonists and target two or more receptors. In some embodiments, one or both peptides comprise partial agonistic or antagonistic activity. Other embodiments herein relate to methods for screening and / or identifying peptides that have biological activity and / or agonistic activity to a receptor disclosed herein.

The invention provides a polypeptide, a derivative of the polypeptide or a pharmaceutically acceptable salt of the polypeptide, and also provides a pharmaceutical composition which contains the polypeptide or the derivative of the polypeptide or the pharmaceutically acceptable salt of the polypeptide and pharmaceutically acceptable auxiliary materials. The polypeptide, the polypeptide derivative or the pharmaceutically acceptable salt and the composition are applied to the field of disease prevention / treatment.

This invention discloses nucleic acid fragments, recombinant vectors, recombinant cells, and recombinant procalcitonin antigen, as well as their preparation methods and applications, relating to the field of procalcitonin preparation. The amino acid sequence of the recombinant procalcitonin antigen is shown in SEQ ID NO: 1, or the amino acid sequence of the recombinant procalcitonin antigen is obtained by attaching a protein purification tag to the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID NO: 1. The recombinant procalcitonin antigen provided by this invention has higher expression levels and purity.

To provide compounds that stimulate both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, making them suitable for treating diabetes, obesity and / or dyslipidemia.SOLUTION: The present disclosure provides compounds with specific sequences, serving as dual amylin and calcitonin receptor agonists. The present disclosure also includes pharmaceutical compositions containing the compounds and therapeutic uses of the compounds and compositions.SELECTED DRAWING: None